OXB.L - Oxford BioMedica PLC

LSE - LSE Delayed Price. Currency in GBp
10.40
+0.36 (+3.59%)
At close: 4:35PM GMT
Stock chart is not supported by your current browser
Previous Close10.04
Open10.10
Bid9.50 x 2513500
Ask12.50 x 11600000
Day's Range9.97 - 10.72
52 Week Range3.77 - 11.54
Volume8,629,497
Avg. Volume5,776,809
Market Cap322.72M
Beta-1.52
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Oxford BioMedica PLC (LON:OXB): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.last month

    Oxford BioMedica PLC (LON:OXB): Has Recent Earnings Growth Beaten Long-Term Trend?

    Today I will take a look at Oxford BioMedica PLC’s (LSE:OXB) most recent earnings update (30 June 2017) and compare these latest figures against its performance over the past fewRead More...

  • Is Oxford BioMedica PLC’s (LSE:OXB) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.2 months ago

    Is Oxford BioMedica PLC’s (LSE:OXB) Balance Sheet Strong Enough To Weather A Storm?

    Oxford BioMedica PLC (LSE:OXB) is a small-cap stock with a market capitalization of GBP £273.38M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • Reuters7 months ago

    Oxford BioMedica wins big contract for Novartis cell therapy

    Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019. The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability. The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukaemia that is expected to reach the market this year.